Proteomics involves the identification of unknown proteins following their separation, often using two-dimensional electrophoresis, digestion of particular proteins of interest by trypsin, determination of the molecular weight of the resulting peptides, and database searching to make the identification of the proteins. Application of proteomics to Alzheimer's disease (AD), the major dementing disorder of the elderly, has just begun. Differences in protein expression and post-translational modification (mostly oxidative modification) of proteins from AD brain and peripheral tissue, as well as in brain from rodent models of AD, have yielded insights into potential molecular mechanisms of neurodegeneration in this dementing disorder. This review surveys the proteomics studies relevant to AD, from which new understandings of the pathology, biochemistry, and physiology of AD are beginning to emerge.
and antioxidants inhibit: protein oxidation (Yatin et al. 1999) ; lipid peroxidation (Lauderback et al. 2001; ; reactive oxygen species production ; and many other markers of oxidative stress (Butterfield 2002) .
Protein oxidation occurs in AD brain in relation to the histopathology of the disease, i.e. protein oxidation occurs in brain regions rich in Ab (for example hippocampus; inferior parietal lobule), but not in Ab-poor cerebellum (Hensley et al. 1995) . However, until now, the identity of these oxidized proteins and their potential relationship(s) to the pathology and the biochemical alterations in AD brain has remained elusive. Initial attempts to identify oxidized proteins employed immunoprecipitation of candidate proteins to determine if they had more protein carbonyls (an index of protein oxidation Butterfield & Stadtman 1997) than did the corresponding protein from control brain (Aksenov et al. 2000; Aksenov et al. 2001) . However, such approaches are highly time consuming, require a prior knowledge (or good guess) of the specifically oxidized protein, and necessitate the availability of an appropriate antibody. These limitations spurred our laboratory to seek modern, data baserelated means for the identification of specifically oxidatively modified proteins. For this purpose, we turned to proteomics.
In this review, we present the methods of proteomics and their applications thus far reported in AD. Insights into potential mechanisms for AD pathology and biochemical abnormalities have been gained and are discussed as well. Finally, we conclude with our thoughts of some of the future prospects for proteomics studies relevant to AD.
Proteomics tools

Two-dimensional (2D) gel electrophoresis
Since the technique of two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) was introduced for separation of proteins in biological samples into single detectable protein spots, this analytical method has been widely used in the process of examination of complex protein mixtures (Rabilloud 2002) . A variety of modifications have been introduced to improve the results of this technique, which consists of a first step, isoelectric focusing (IEF), that separates proteins according to their isoelectric point, and a second step, SDS-PAGE, that provides a further separation of proteins depending on their size. The result is a two-dimensional map, in which each spot most often corresponds to a single protein. The main information that is obtained from a 2D-PAGE map is protein profiling, which allows comparison between different samples in order to identify differences in protein expression (Tilleman et al. 2002a) . In addition, 2D-PAGE is used to create maps from organisms or subcellular organelles within cells in order to catalogue proteins and create databases that can be widely used (Kaji et al. 2000) .
The success of 2D-PAGE relies in its ability to resolve thousand of proteins at once, providing important clues even for post-translational modifications that involve changes in protein total charge. The continuous modification and improvement of the technique has made 2D-PAGE a reasonably reliable method, but this approach still presents many challenges to overcome. The solubilization process for proteins is the main obstacle, because the IEF does not permit introduction of charge (from ionic detergents) that can interfere with the focusing process. The use of chaotropic agents, such a urea and thiourea, coupled with non-ionic or zwitterionic detergents, provides a good solubilization medium and avoids protein precipitation during the IEF and in the process of protein transfer from the IEF gel into the SDS gel. Protein solubilization issues are most severe with regard to membrane proteins that need to be investigated. Few studies report the successful obtainment of membrane protein maps (Santoni et al. 2000) , and the methods fail to provide a reliable tool for solubilization and resolution of bilayers. On the positive side, immobilized pH IEF strips, introduced to replace the previously used gel tubes containing ampholytes, eliminate the typical 'cathodic drift' during IEF and increase the map reproducibility between samples (Molloy 2000) . However, the limited pH range (usually 3-10) that the strips provide precludes the detection of proteins that fall in the very basic range, although recently some companies that sell 2D-PAGE tools provide strips in the basic pH range. Improved resolution of map spots representing proteins of close isoelectric points may be possible with use of narrow range pH strips (as low as 1 pH unit). Additionally, the limited mass range and the detection limits also represent technical limitation of the method. Finally, low-abundant proteins still remain absent on the map and thus silent for proteomics analysis, representing a fundamental challenge when proteomics is applied to disease, in which low-abundant proteins can often play an important role.
Alternative techniques, that do not involve the 2D gel separation, are also available. HPLC is often used to achieve separation of peptides produced by trypsin digestion of a protein mixture. The technique, referred to as 2D-HPLC, utilizes a series of columns that obtain separation of the peptides that then are submitted for mass spectrometry analysis. Evaluation of protein expression can also be achieved by previously labeling a mixture of two samples with compounds that bind to specific amino acid side chains, generating a mass spectrometry distribution of masses that allows evaluation of the differences in expression of a protein in two samples. This technique is referred as isotopically coded affinity tags (ICAT) (Smolka et al. 2001) .
In our proteomics approach to identify specifically oxidized proteins, we applied 2D-gel electrophoresis, paralleled with immunochemical detection of protein carbonyls, followed by mass spectrometry analysis, as shown in Fig. 1 .
Identification of proteins containing reactive carbonyl groups in AD and control brain samples is determined by 2D Oxyblot analysis, in which the proteins are transferred from the gel to a membrane with subsequent testing of carbonyl reactivity by using specific antibodies. 2D Oxyblots and the subsequent 2D gel images are matched and the anti-DNP immunoreactivity of individual proteins are normalized to their content, obtained by measuring the intensity of colloidal Coomassie blue staining. This procedure allows comparison of oxidation levels of brain proteins in AD versus control subjects.
Mass spectrometry and database searching
Once the protein map is obtained, the protein of interest, separated from the mixture into a single detectable spot, needs to be eluted from the gel to undergo mass spectrometry analysis. The most common methods to obtain the protein from an excised spot utilize the procedure of in-gel digestion, in which a protease, solubilized in a buffer that optimizes the digestion, is absorbed into the gel surface to cleave the protein into several peptides. This procedure has a double advantage: first, the recovery is much higher when the protein is cleaved in smaller particles; more importantly, collection of peptides that result from sequence-specific proteolysis is an important means to identify the protein itself, because their masses constitute mass fingerprints that are characteristic of a particular protein. This process, called peptide mass mapping, strictly involves the use of MS together with a suitable database (see Table 1 ) containing protein sequences to which the experimental masses are compared.
The mass spectrometry tool allows important information on proteins to be obtained, such as peptide masses and amino acid sequence, which are necessary to identify the protein of interest. Until a few years ago, the commonly used ionization techniques failed to provide an accurate peptide mass due to molecular fragmentation of the sensitive ion. The recent introduction of 'softer' ionization techniques has rendered mass spectrometry the indispensable tool for protein identification studies. The two techniques most often employed are MALDI (matrixassisted laser desorption/ionization) and ESI (electrospray ionization). In MALDI, the peptide sample is mixed to a matrix (usually a-cyano-4-hydroxycinnamic acid or 2,5-dihydroxybenzoic acid) and deposited to a plate that is subjected to laser radiation. The chromophores (¼ highly UV absorbents) incorporate high energy that is then released to the peptides. The latter evaporate as detectable MH + ions, due to the acidic nature of the matrix, which donates a proton in the gas phase via mechanisms that are not well understood. The process can be automated, but may require a desalting step to eliminate impurities from the sample. In ESI, a very high potential difference is established between the MS inlet and a microcapillary tube, through which the liquid sample flows. The potential difference causes the dispersion of the liquid released by the capillary into fine droplets. These droplets undergo solvent evaporation until droplet fission occurs, due to the high charge to surface tension ratio, ultimately ending in the formation of a single detectable ion. This process requires low salt concentration in the sample of interest and presents the advantage of allowing on-line preseparation of the peptides with HPLC. In addition, the flow rate can be reduced to nanoliters per minute, thereby increasing the time available for analysis. Information about the protein can be amplified or confirmed by further isolation of a single peptide and fragmentation. This process is often referred as tandem MS, and offers insight into protein identity and sequence (Aebersold and Goodlett 2001) .
In MS/MS analysis, a single ion is isolated and fragmented, and the fragments are detected in order to obtain information on the structure of the substance of interest. Once all the ions are collected, the ion of interest is isolated, ejected from the trap and fragmented in an excitation step. The isolation occurs by applying a large range of frequencies at once, except the resonating frequency of the desired ion, which will be the only one to be retained in the trap. The next step is fragmentation of the isolated ion, which provides additional information necessary for protein identification or for evaluation of possible protein modification.
An additional proteomics tool in which mass spectrometry is utilized is surface-enhanced laser desportion/ionization (Merchant and Weinberger 2000) . This system can be used to screen biomarkers from a variety of complex samples including blood, urine, serum, plasma, etc. Additionally, the technique requires a small sample volume and has detection limits at the attomolar level. SELDI can also be used to detect post-translational modifications such as glycosylation and phosphorylation by screening for particular mass shifts in the protein peaks; however, it is dependent upon a change in the expression profiles between samples and is limited because the technique cannot be used to specifically identify a protein that is differentially expressed, and isolation of the protein itself is required (Issaq et al. 2002) . Moreover, SELDI is limited to detection of proteins of relatively low molecular mass (Issaq et al. 2002) .
The information retrieved by mass spectrometry analysis, that is, a list of peptide masses, then enters the 'informatics' step of the proteomic analysis, which involves on-line protein or genomic databases. One of the widest protein sequence database is the SwissProt (Hoogland et al. 2000) , to which it is possible to submit a protein identification request by using identification tools based on computer algorithms that are freely accessible through the internet. Examples of these tools are reported in Table 1 with the respective web site. The purpose of these search engines is to provide a theoretical protease digestion of the proteins contained into the database and compare the resulting peptide masses to the experimental masses obtained from the in-gel digested proteins. The analysis is not a simple comparison of peptide masses, because it takes into account several factors, such as the protein size and the probability of a single peptide to occur in the whole database. For each entry, the search engine produces a probability score, which is calculated by a mathematical algorithm that is specific for each search engine. Any hit with a score higher that the one obtained from the search, which is usually set for p < 0.05, has a legitimate chance to be the protein cut from a given spot. Of course, false identification may occur, and to avoid that circumstance, one should always consider the information obtained from the 2D map, that is, molecular weight and IP range.
With the production of more databases, it is our opinion that bioinformatics will occupy a leading position among all the proteomics-related tools. Additional information and links between different sets of information will be available, making informatics searching the most powerful resources for speed, variety of data, and reliability.
Protein expression and Alzheimer's disease
Proteomics has become an invaluable resource in the investigation of neurodegenerative diseases. Expression proteomics, in particular, has enabled researchers to compare and contrast various conditions due to the ability to quickly and reproducibly map, screen, quantitate, and identify a vast number of proteins at once. Such principles have been utilized in order to detect specific alterations in the protein expression levels of various regions of the AD brain compared to control brain, which may, in turn, facilitate an explanation of the mechanisms by which the disease progresses.
Specifically, a large body of this work has been reported by Lubec et al. (1999) (see Table 2 ). Their laboratory has identified a number of protein expression alterations in the AD brain, which help to elucidate possible mechanisms rationalizing the pathogenesis of the disease. However, this group tends to look for alterations in specific proteins by using total immunoreactivity rather than screening an entire set of proteins at once and attempting to identify them by mass spectrometry, which is often easier and faster.
In addition to the pathophysiological hallmarks of the disease, which are well documented, AD is associated with synapse loss, oxidative stress, decreased glucose metabolism, mitochondrial deficit, increased protein misfolding, and decreased protein turnover. The expression alterations observed in many proteins involved in a number of pathways help to develop testable hypotheses of neurodegenerative mechanisms in AD brain as is discussed in the following sections of this review.
Altered energy metabolism
The accumulation of glycolytic enzymes such as a-and c-enolase and glyceraldehyde 3-phosphate dehydrogenase confirms the indication that glucose metabolism is affected in AD (Schonberger et al. 2001) . Additionally, the decrease in the expression of voltage-dependent anion-selective channel protein-1 (VDAC-1), which is responsible for the regulation of mitochondrial metabolism by manipulating the ion flux of metabolites such as ATP, supports this hypothesis (Yoo et al. 2001a) . Decreased glucose metabolism is also associated with the decrease in expression of the 24-and 75-kDa subunits of the multiprotein enzyme complex NADH: ubiquinone oxidoreductase, more commonly known as complex I of the mitochondrial electron transport chain. The complex is located on the inner mitochondrial membrane and is responsible for the flow of electrons from NADH to ubiquinone in the initiating steps of oxidative phosphorylation to produce ATP (Kim et al. 2001d) . A decrease in complex I expression, consistent with altered message (Aksenov et al. 1999) , may result in impaired ATP production as well as a decrease in the activity of the entire electron transport chain. This, in turn, may result in the departure of electrons from their carrier molecules to generate reactive oxygen species (ROS). ROS production due to the decreased expression of complex I suggests an alternative rationalization for the well-documented existence of oxidative stress in AD (Kim et al. 2001d; .
Altered antioxidant expression
An increase in the expression of several antioxidant proteins was also observed in the AD brain, which agrees with the premise of oxidative stress in the pathogenesis of the disorder Butterfield 2002; ). An increase in carbonyl reductase (CBR), alcohol dehydrogenase (ADH), peroxiredoxin-I (Prx-I), peroxiredoxin-II (Prx-II), antioxidant protein 2, and Cu/Zn superoxide dismutase was detected (Balcz et al. 2001; Kim et al. 2001b; Schonberger et al. 2001; Krapfenbauer et al. 2003) . Moreover, a decrease in peroxiredoxin-III (Prx-III), metallothionein-1 (MT-1), and metallothionein-3 (MT-3) expression was found Prange et al. 2001) . CBR and ADH are cytosolic enzymes that catalyze the reduction of carbonyls to their corresponding alcohols. Carbonyls are generally toxic metabolic intermediates that serve as a marker of oxidative stress (Butterfield and Stadtman 1997 ).
An elevation in the expression of the enzymes involved in the removal of these cytotoxic intermediates suggests an adaptive mechanism of up-regulation to counteract the accumulation of these species (Balcz et al. 2001) . Prx-I and Prx-II play an important antioxidant role in the protection of neurons from damage induced by hydrogen peroxide. The up-regulation of these enzymes is consistent with a role of ROS in the pathogenesis of AD. However, Prx-III, found only in mitochondria, was decreased in AD brain. This could be due to damage to the enzyme caused by ROS produced within the mitochondria ).
MT-1 and MT-3 are proteins with antioxidant function with respect to the clearing of heavy metals. The reduced expression of these proteins is consistent with the notion that metals in AD brain may play a role in this disorder Prange et al. 2001; Bush 2003) .
Altered synaptic function
Synaptic dysfunction and alterations in neuronal growth in AD can be related to the decrease in nucleoside diphosphate kinase-A (NDPK-A), 2¢,3¢-cyclic nucleotide-3¢-phos- , drebrin, and a-endosulfine. NDPK-A has been reported to be colocalized with microtubules and is believed to be involved in neuronal cell proliferation and neurite outgrowth (Kim et al. 2002) . CNPase is associated with oligodendrocytes and therefore myelination (Vlkolinský et al. 2001) . Snap-25 is believed to play a role neurotransmission via the exocytosis and docking of synaptic vesicles (Greber et al. 1999) . TCP-1 is a protein complex involved in the folding of actin and various isoforms of tubulin (Schuller et al. 2001) , while stathmin is responsible for the integration of multiple signal transduction cascades and the destabilization of microtubules (Cheon et al. 2001) . NF-L is a protein implicated in maintaining the integrity of the neuronal cytoskeleton (Bajo et al. 2001) . Drebrin is a dendritic spine protein that modulates synaptic plasticity (Shim and Lubec 2002) . a-Endosulfine is an endogenous regulator of ATP-sensitive potassium channels (Kim and Lubec 2001e ). All of the above alterations reported in AD could result in the loss of synaptic function, cognitive decline, and neuronal death.
Neurotransmitter and receptor dysfunction
Cognitive decline is associated with neurotransmitter imbalances and neuronal death, both of which can be explained by changes in protein expression levels. Histamine-releasing factor (HRF), which regulates the release of the neurotransmitter histamine, is expressed ubiquitously throughout the brain. The decrease in HRF expression may be associated with cognitive decline indicating that histamine plays a role in whole-brain function (Kim et al. 2001a) . The a7 and the 26-kDa truncated isoform of the a3 subunit of nicotinic acetylcholine receptors (nAchRs) were significantly reduced in AD brain suggesting the decreased expression may influence the function of cholinergic neurons, which are the most affected in AD (Engidawork et al. 2001a) . Interaction of Ab(1-42) is reported for the a7 nAChR, which regulates acetylcholine release and calcium homeostasis. It has been shown that Ab(1-42) binds to the a7 nAChR with high affinity and the complex is endocytosed resulting in intraneuronal accumulation of Ab (Nagele et al. 2002) . Consequently, Ab exhibits an inhibitory effect on a7 nAChR resulting in altered release of acetylcholine and therefore memory and learning deficits (Tozaki et al. 2002) . Alternatively, the 45-kDa a3 subunit was increased. The expression of the a3 nAChR subunit is normally down-regulated by cAMP via PKA, and the decreased basal level of cAMP and PKA (Kim et al. 2001c) in AD brain results in dysregulation in which the expression of the a3 subunit goes unchecked and increases (Engidawork et al. 2001a ).
Apoptotic and anti-apoptotic regulation
Apoptosis plays a major role in the neuronal loss exhibited in AD. The pro-apoptotic proteins zipper-interacting protein kinase (ZIPK), Bcl-2-interacting mediator of cell death/Bcl-2 related ovarian death gene (Bim/BOD), and the receptor interacting protein (RIP)-like interacting CLARP kinase (RICK) were found to be increased in AD brain while the anti-apoptotic protein p21 is up-regulated in response to oxidative stress (Engidawork et al. 2001c) . p21 is believed to involve the inhibition of the MAPK/JNK pathway, which has been shown to be activated in AD brain and by Ab peptide in vitro (Morishima et al. 2001) . The anti-apoptotic protein Bcl-2 is up-regulated in the cerebellum only of the AD brain suggesting a mechanism by which this area of the brain is less affected in AD (Hensley et al. 1995; Engidawork et al. 2001c) . Likewise, the apoptosis repressor with caspase recruitment domain (ARC) was also up-regulated as an anti-apoptotic mechanism in response to apoptotic signals such as Ab peptide. Conversely, the Fas associated death domain (FADD)-like interleukin-1b-converting enzyme inhibitory protein (FLIP) was decreased due to the fact that it is a substrate for caspases and forms inactivating complex with caspase-8. Additionally, the anti-apoptotic protein DNA fragmentation factor 45 is decreased due to degradation by caspase-3. The down-regulation of FLIP and DFF45 also provides supporting evidence for the activation of caspases as well as the down-regulation of procaspases-3, -8, and -9 (Engidawork et al. 2001b) . Finally, glial fibrillary acidic protein (GFAP), a marker of glia, was elevated in AD brain, supporting the hypothesis of neuronal cell death (Greber et al. 1999; Tsuji et al. 1999) .
Chaperone proteins
AD is also associated with protein misfolding and decreased protein turnover. This can be related to the dysregulation of molecular chaperone proteins in the AD brain such as heat shock protein 60 (HSP60), heat shock conjugate 71 (HSC 71), glucose regulated protein 75 (GRP75), and alpha crystalline B, all of which are down-regulated. Conversely, heat shock protein 70 RY (HSP 70 RY) and glucose regulated protein 94 (GRP 94) are up-regulated . Down-regulation of HSP60 (resident in mitochondria) conceivably could be related to oxidative stress as noted above.
Additional studies
For AD research using proteomics, brain is not the only tissue that has been examined in order to elicit protein expression changes. Blood plasma samples have been examined for apolipoprotein E (ApoE), tau, and presenillin 2 in order to develop a less invasive screening process for AD (Ueno et al. 2000) . Cerebral spinal fluid has also been used to determine differences between control and AD patients (Davidsson et al. 2002) . Several significant protein expression changes were determined in this study, including a decrease in the isoforms of ApoE and pro-apolipoprotein, suggesting that there may be a decrease in these levels in the brain as well (Davidsson et al. 2002) . Additionally, less traditional proteomics tools have been utilized in the study of AD. For example, SELDI has been used to demonstrate that presenilin 1(PS1) plays a role either directly or indirectly in the production of Ab as either c-secretase itself or in the function of c-secretase, respectively (Chen et al. 2000) . Also, SELDI has shown that BACE1 is the primary neuronal b-secretase (Cai et al. 2001) and that an increase in intracellular cholesterol in cells transfected with APP increases the production of Ab1-42 (Austen et al. 2000) .
It is important to note that the expression changes, which have been detected in AD, do not provide information regarding the integrity of the function of the proteins themselves and these changes are not global, but correspond to specific brain regions. Consequently, protein expression changes provide only a clue as to altered state of the protein that the disease causes. More research is required to determine if these proteins are modified, in some way, which would result in loss of function (i.e. oxidation). For example, up-regulation of antioxidant proteins such as CBR, ADH, Prx-I, Prx-II, antioxidant protein 2, and Cu/Zn superoxide dismutase may be a compensatory action; however, if the proteins do not function properly the up-regulation is all for naught. Additionally, increased expression may be due to decreased protein turnover, which has been implicated in AD. Nevertheless, this work has validated the association of altered energy metabolism, decreased synaptic function, and oxidative stress in AD; however, this work has provided only a beginning from which researchers can, in future studies, determine how these individual alterations affect the system. In summary, the expression of many proteins is altered in the AD brain resulting in a cascade of alterations on multiple pathways within the brain. Perhaps it is the relationship between these pathways that maintains the careful balance between neuronal survival and neuronal death. To date proteomics has shed light on only a small portion of the puzzle; however, with improved techniques that allow for increased solublization and loading of membrane bound proteins and very basic proteins along with better detection limits, more information will become available to rationalize the pathogenesis of AD.
Proteomic studies on oxidatively modified proteins in AD
In AD brain, protein oxidation is increased as indexed by protein carbonyls ) and 3-nitrotyrosine (Smith et al. 1997; Castegna et al. 2003) . The detection of markers of oxidation in AD brain, which clearly shows the importance of oxidative stress in the progression of the disease , still does not provide evidence on how oxidized proteins, lipids and DNA might affect cellular metabolism and ultimately lead to synaptic loss and neuronal death, known events in AD. Identification of specifically oxidized proteins in AD brain allows one to determine which proteins are more affected by oxidation in AD and, consequently, more prone to inactivation, and thus represents a significant step in linking well-established AD neurodegeneration with oxidative events at a protein level. A first and more traditional approach to reach this goal has been obtained in our laboratory by Aksenov et al. (2000 Aksenov et al. ( , 2001 , who identified creatine kinase BB and b-actin as specific targets of protein oxidation by coupling immunochemical quantification of protein carbonyls with immuno-detection of the protein position on the 2D gel. This procedure, successful in this specific case, unfortunately fails to identify proteins on a large scale, requiring laborious staining with specific antibodies and logical guessing of the antibody to be used.
The first use of proteomics to identify specifically oxidized proteins in AD brain led to the identification of several specifically oxidized proteins: creatine kinase BB (CK), glutamine synthase (GS), ubiquitin carboxy-terminal hydrolase/L (UCH/L), a-enolase, and dihydropyrimidinase related protein 2 (DRP2) (Castegna et al. 2002a (Castegna et al. , 2002b . Our approach to identifying modified proteins in AD brain has been recently applied to detect specific markers of nitrosilation, successfully detecting, with a specific antibody against 3-nitrotyrosine, three targets of protein modification: neuropolypeptide h3, triosephosphate isomerase and a-enolase (Castegna et al. 2003) .
Plausible mechanisms of neurodegeneration in AD brain, summarized in Figure 2 can be generated based on each of these specifically oxidized proteins. Classes of specifically oxidatively modified proteins thus far identified in AD brain range from those dealing with energy metabolism, to excitotoxicity, to recycling of damaged or aggregated proteins through the proteasome, to membrane structure and apoptosis, to neuronal communication. Moreover, some of the pathological characteristics of AD brain, such as accumulation of aggregated, damaged proteins, excess ubiquination, and shortened dendritic lengths are consistent with putative dysfunction of some of these specifically oxidized proteins. The assumption involved is that oxidative modification affects protein function. This assumption is proven correct for three cases thus far investigated in our laboratory: CK and GS (Hensley et al. 1995) and the glutamate transporter, EAAT2 (Lauderback et al. 2001) .
Proteins involved in energy metabolism
Creatine kinase (BB isoform), a-enolase, and triosephosphate isomerase are directly or indirectly involved in ATP production, and if, like CK, the enzymatic activity of these other energy-related enzymes is diminished in AD brain, ATP production will be compromised. This may be important especially to the synapse, the probable initial site of attack in neurons in AD (Mattson et al. 2001) . Ion pumps, electrochemical gradients, the cell potential, voltage-gated ion channels, phospholipid asymmetry, and many other aspects of the neuron would be compromised by diminished ATP levels. Neurodegeneration, following influx of Ca 2+ and subsequent Ca 2+ -dependent degradative processes, would ensue.
Protein involved in glutamate reuptake
We previously showed that EAAT2 in AD brain was oxidatively modified by the lipid peroxidation product, 4-hydroxy-2-trans-nonenal (HNE) (Lauderback et al. 2001) . Interestingly, Ab(1-42) induced the same modification to this glutamate transporter (Lauderback et al. 2001) , and we and others showed that Ab(1-42) induced HNE formation (Mark et al. 1997; Lauderback et al. 2001) . Since HNE addition to synaptosomal membranes leads to altered protein conformation (structure) (Subramaniam et al. 1997) , this oxidative modification of EAAT2 in AD brain likely explains the loss of activity of this transporter (Masliah et al. 1995) . This result, coupled with the loss of activity of GS in AD brain previously reported by us (Hensley et al. 1995) and others (Smith et al. 1991) , and now explained by the oxidative modification of this enzyme (Castegna et al. 2002a) , would lead to excess glutamate on the outside of neurons. Stimulation of the NMDA receptor by this excess glutamate would lead to influx of Ca 2+ , with immense effects on LTP (and learning and memory), organelle structure, and subsequently neuronal death via excitotoxicity.
Proteasomal dysfunction
The proteasome system in AD brain is dysfunctional (Keller et al. 2000) . The consequences of a dysfunctional proteasomal degradation system in AD brain would be the build up of damaged or aggregated proteins, with subsequent loss of neuronal function (Shringarpure et al. 2001) . One means by which the proteasomal system might be compromised in AD is the excess HNE-bound proteins present. The 'grease' associated with this alkenal bound to proteins, or potential cross-links between protein-bound HNE and the proteasomal proteins [recall there is a free carbonyl on HNE that could react with lysine amino groups to form a Schiff base (Butterfield & Stadtman 1997) ] would clog the pore of the proteasome. Additionally, loss of activity of UCH L-1, a specifically oxidatively modified protein in AD brain, would lead to excess protein ubiquitination (found in AD), loss of activity of the proteasome (found in AD), and accumulation of aggregated or damaged proteins (found in AD).
Lipid abnormalities and cholinergic failure
Phospholipid asymmetry is essential for membrane structure and function (Daleke and Lyles 2000) . Neuropolypeptide h3, a specifically oxidatively modified protein in AD brain (Castegna et al. 2003) , has a role as a phosphatidylethanolamine binding protein. It is conceivable that loss of activity of this protein activity as a consequence of its oxidative modification could compromise phospholipid asymmetry in AD brain. If so, phosphatidyl serine would become exposed on the outer lamellae of the membrane, and this phospholipid is a signal to initiate apoptosis. Neuronal death could result. Neuropolypeptide h3 is also the hippocampal cholinergic neurostimulating peptide, one function of which is to stimulate choline acetyltransferase. This latter enzyme was one of the earliest biochemical abnormalities reported in AD brain (Davies 1999 ). Although we reported earlier that HNE was bound to cholineacetyltransferase upon interaction of Ab(1-42) with synaptosomes , thereby possibly explaining the loss of activity of this enzyme in AD brain, it also is conceivable that oxidative modification of neuropolypeptide h3 contributes to the loss of cholineacetyltransferase activity.
Neuritic abnormalities
Many years ago, shortened dendritic lengths were ascribed to AD neurons (Coleman and Flood 1987) . What might be some of the consequences of shortened dendritic lengths? One consequence that might be expected would be decreased interneuronal communication, which conceivably could be important in a disorder like AD in which memory loss is so characteristic. Dihydropyrimidinase-related protein 2, a specifically oxidatively modified protein in AD brain (Castegna et al. 2002b ) and whose expression is increased in AD , performs two important functions in neurons. DRP2 interacts with and modulates the activity of collapsin, a protein that elongates dendrites and directs them to adjacent neurons. This protein may also be involved in neuronal repair. Normally, this protein is highly expressed during brain development, but rarely in adult brain. One can conceive of a scenario in which the neuron, under oxidative attack and subsequent synaptic loss, requires new synapses to be formed. Thus, DRP2 would be expressed in large amounts, but, as is the case with CK (Aksenov et al. 2000) , as soon as it is expressed, it would become oxidatively modified and lose function. Hence, dendritic lengths would be shortened, and memory conceivably would decline.
Thus, proteomics analysis of post-translationally modified proteins (in this case oxidative modification) in AD brain led to the identity of proteins, whose decreased function (if diminished as a consequence of the oxidative modification), are consistent with the pathophysiology of AD.
Other laboratories have recently applied the same technique to identify oxidized proteins in AD. Choi et al. (2002) recently identified in AD plasma two targets of protein oxidation: isoforms of fibrinogen gamma-chain precursor protein and of alpha-1-anti-trypsin precursor, proteins that have already been implicated in the pathology of this neurodegenerative disorder. This discovery suggests the intriguing possibility of using oxidized proteins in plasma as markers for AD. A recent study on AD brain also identified targets of protein oxidation, although no specific identification of the oxidized proteins was achieved (Korolainen et al. 2002) .
Proteomics on rodent models of AD Several proteomic approaches have been performed in order to identify changes in the level of protein expression of brain proteins in relation to the mutation that renders the rodent a suitable model for AD. Although studies on changes in protein oxidation are under investigation in our laboratory, some publications on changes in protein expression in rodent models of AD are currently available (see below). We anticipate a future development of this area with an increase of publications reporting results based on proteomics analysis.
An interesting study on the glycogen synthase kinase-3b (GSK-3b) transgenic mouse has been performed by Tilleman et al. (2002a) , whose results have been published together with a second publication on proteomics applied to the tau transgenic mouse (Tilleman et al. 2002b) . GSK-3b is a phosphorylating enzyme involved in several physiological processes and has been implicated in AD, as its involvement in phosphorylating the tau protein in vitro and in situ has been discovered. Tau protein is the main constituent of neurofibrillary tangles (NFT) when phosphorylated, and a large body of evidence indicates GSK-3b as the principal candidate as tau kinase in neurons under physiological conditions. The first study utilized proteomics to gain information on which proteins are more affected in level of expression by overexpressing GSK-3b in a mouse. The results were then compared to the second proteomic study, in which the model used is a mouse overexpressing human tau. Eleven proteins were identified in both transgenic mice and among those, four were differently regulated in the two models. Enolase-1 and D-3-phosphoglycerate dehydrogenase were up-regulated in both cases, showing how the mutation affects energy metabolism, the alteration of which is also a known event in AD brain. NADH-ubiquinone oxidoreductase was down-regulated only in the GSK transgenic mouse, showing an opposite trend to the tau transgenic mouse, in accordance with the finding that mitochondria are accumulated in the human tau transgenic mouse. More direct effects on protein levels were seen in the GSK mouse in term of components of microtubules being affected by the mutation, indicating that the neurodegeneration and axonopathy is not actually fully developed in the tau transgenic mouse. The studies provide clues into the effect of the mutations and reveal the protein level abnormalities when NFTs are still not produced. Skehel et al. (2000) recently published results from the application of proteomics to the apolipoprotein E*3-Leiden mouse, in which the apoE form presents an abnormal insertion of seven amino acids in its primary structure, and additionally bears an arginine at position 112 instead of cysteine. The study showed a difference in some protein levels in the mutant mouse compared with the wild type, although no protein is identified yet (Skehel et al. 2000) . However, this study shows a promising way to demonstrate the effect of the mutation on the protein pattern following hyperlipoproteinemia, which is a consequence of variant apoE .
Additional studies have been performed to provide reliable databases of proteins in mice, among which one showed 2D-profiling of portions of mouse brain during aging, form the 10th to the 24th week of life . The investigation presented a very complete mouse database identifying new proteins in cerebellum, cerebral cortex, hippocampus, striatum and cervical spinal cord, and offering a very useful tool for comparison and identification of the proteins that may play an important role in disease.
Proteomics studies on proteins thought to play a role in AD The application of proteomics is lately showing its versatility in studying specific proteins, the function of which may play an important role in the pathological mechanism of neurodegeneration in disease. Screenings of protein expression and protein oxidation in AD, studies already published, are not the only target of neuroproteomics. Lately, several studies have been applying the techniques of electrophoresis, coupled with mass spectrometry, to specific enzymes in order to identify their role, their mechanism of action and their relationship with other proteins in the brain. A literature search has identified few studies that apply proteomics to AD brain proteins, although some investigations present the inconvenient necessity of isolating the protein of interest from the AD brain. Brining et al. (1999) address the problem with structure and toxicity of amyloid b (Ab) peptide, that shows toxicity in cell culture and aggregates of the peptide bind to Congo red (CR). These authors investigated toxic Ab and non-toxic Ab, by using non-denaturing gel electrophoresis. The mobility of the peptide as a function of the gel concentration was plotted in order to identify any difference in mobility that could be related to size or surface charge. This study reported that the number of isomers for the toxic and-non-toxic forms of Ab are equal, and the CR binding forms present lower negative surface charge and smaller size. These changes demonstrate the tendency of the modified peptides to precipitate due to the lower solubility, although larger size peptides should be more prone to precipitation than smaller ones. A subsequent study (Lund et al. 2001) targeted the other major pathological hallmark of AD, neurofibrillary tangles (NFT) particularly their important constituent, tau protein, the hyperphosphorylation of which is responsible for its dissociation from the microtubule and its precipitation in tangles. Human tau was incubated with recombinant tau protein kinase (TPK) II (cdk5/p20) in vitro to determine the extent of phosphorylation and the specific amino acid residues modified by mass spectrometry. The investigation identified six sites of phosphorylation by TPK II that led to speculation of a possible hierarchical order of phosphorylation. This would suggest modification of some sites might be required for successive phosphorylation of other residues of tau. Additionally, the study confirmed the role of TPK II in phosphorylating many tau sites that are modified in AD, in accordance with a previous study (Hanger et al. 1998 ) that showed identification of 22 phosphorylation sites in PHF-tau purified from AD brain. As noted above, phosphorylation of tau in vitro by GSK-3a has been also investigated in relation with the possible differential effect of apolipoprotein E (apoE) isoforms (Gibb et al. 2000) . This study was based on the hypothesis that apoE may protect tau from hyperphosphorylation in an allele-specific way, a hypothesis supported by previous data that showed an allele-specific variation in the in vitro binding of apoE to tau (Strittmatter et al. 1994) . The investigators performed phosphopeptide map analysis of recombinant human tau phosphorylated by GSK-3b and provided further evidence that apoE influences tau phosphorylation in such a way that apoE 4 resulted in a different degree of phosphorylation depending on the specific sites. This study demonstrated that apoE 4 binds differently to tau, thus affecting the above-mentioned hierarchic succession by which tau is modified in its phosphate content. Although further studies are required to determine the significance of apoE-tau interaction in vivo, this proteomics finding relates the differential binding of apoE4 to tau to its known higher frequency in patients with AD compared to apoE 3 and 2.
Additional studies on important proteins in AD have been performed by isolating the protein of interest from the AD brain with proteomics techniques, such as preparative gel-electrophoresis and gel electroelution that was followed by mass spectrometry analysis. The two more significant studies involve apoE4 and b-tubulin. Hesse et al. (2001) characterized apoE4 isolated from AD cerebrospinal fluid (CSF) and confirmed through MS analysis the known change of Cys to Arg in position 112 of apoE4, a change that reflects the increased frequency of the apoE4 allele in the AD population. A similar study (Vijayan et al. 2001 ) was performed to provide clues on the status of b-tubulin isolated from AD brain. Mass spectrometry analysis identified btubulin as an abnormally hyperphosphorylated protein in AD brain, confirming the hypothesis of an involvement of btubulin in the disassembly of the microtubules (MT). Brain tubulin loses its ability to assemble MTs in AD, an ability that is regained when dephosphorylation occurs (Wandosell et al. 1986 ). In the brain of AD patients, even a small amount of modified tubulin may play an important role in the process of MT disassembly.
Future of neuroproteomics in Alzheimer's disease
The proteomics studies noted above, which use these emerging methods as major resources to give insights into AD, provide important clues on particular proteins involved in AD pathology. The findings contribute to the effort to establish a relationship between pathological hallmarks of the disease and metabolic or structural abnormalities, which are strictly dependent on significant proteins. Post-translational modification of proteins that can be identified by proteomics is a new approach to gain insight into molecular mechanisms involved in this dementing disorder. The information obtained by proteomic analysis offers the possibility of establishing new hypotheses for the mechanisms of neurodegeneration found in AD brain in which particular proteins play a key role. It is difficult from proteomics analysis of AD brain alone to establish a hierarchy of altered proteins, i.e. which protein alteration is the primary event and which are secondary phenomena. Indeed, proteomic analysis of AD brain, particularly identification of oxidatively modified proteins, has just begun (Castegna et al. 2002a (Castegna et al. , b, 2003 . Consequently, to gain insight into a hierarchical ordering of protein changes, other systems need to be studied to complement the proteomics investigations. For instance, proteomics studies involving animal models relevant to AD and cell cultures will provide additional insight into the roles of Ab(1-42) in this disorder. Rodents with overexpressed, knocked-in, or knocked-out proteins identified as potentially important in AD will play important roles in better understanding AD in our opinion. Such studies are underway in our laboratory and will be reported elsewhere.
